The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells
or T cells genetically engineered to express tumor recognizing receptors has emerged as a …

Autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR)
against human carcinoembryonic antigen (CEA) were administered to three patients with …

T cell receptor-engineered T cell (TCR-T) therapy is free from the limit of surface antigen
expression of the target cells, which is a potential cellular immunotherapy for cancer …

T cells have the capacity to eradicate diseased cells, but tumours present considerable
challenges that render T cells ineffectual. Cancer cells often make themselves …

Therapeutic T cells with desired specificity can be engineered by introducing T-cell
receptors (TCRs) specific for antigens of interest, such as those from pathogens or tumour …

Adoptive transfer of T lymphocytes is a promising treatment for a variety of malignancies but
often not feasible due to difficulties generating T cells that are reactive with the targeted …

The adoptive transfer of antigen-specific T cells that have been expanded ex vivo is being
actively pursued to treat infections and malignancy in humans. The T cell populations that …

The genetic modification of T lymphocytes is an important approach to investigating normal
T-cell biology and to increasing antitumour immunity. A number of genetic strategies aim to …